Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 12/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3097793 | 0.83 | IL2 (0.44) | IL2MEN1KMT2ASTIM1ORAI1 | |
| SCHEMBL8055351 | 0.80 | IL2 (0.42) | IL2JAK1TYK2STIM1ORAI1 | |
| SCHEMBL2816312 | 0.74 | IL2 (0.50) | IL2JAK1TYK2MEN1KMT2A | |
| SCHEMBL3109398 | 0.74 | IL2 (0.41) | IL2MEN1KMT2ANOTUMRORC | |
| SCHEMBL3105817 | 0.71 | IL2 (0.41) | IL2MEN1KMT2ASTIM1ORAI1 | |
| SCHEMBL3103400 | 0.71 | RAB9A (0.45) | IL2MEN1KMT2ARORCNPC1 | |
| SCHEMBL451062 | 0.69 | IL2 (0.62) | IL2 | |
| SCHEMBL647270 | 0.69 | MEN1 (0.38) | IL2MEN1KMT2ASTIM1ORAI1 | |
| SCHEMBL8069094 | 0.67 | STIM1 (0.43) | IL2MEN1KMT2ASTIM1ORAI1 | |
| SCHEMBL11911928 | 0.66 | MEN1 (0.59) | IL2JAK1TYK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273751-A1 | SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273751-A1 | SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, IL5, NLRP1 | IL2 9/4885JAK1 814/4885TYK2 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.